Tango Therapeutics, Inc. Share Price & Technical Analysis
TNGX · $20.24 (-6.38%)
Healthcare / Biotechnology
$20.24
-6.38%
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant P…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-6% return in May, 14% avg return in past 3 year May month.
116% return in 2026, 79% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 30% | -4% | 94% | 3% | -6% | – | – | – | – | – | – | – | 116% |
| 25 | -3% | -28% | -33% | 0% | 69% | 132% | 18% | 16% | 27% | -4% | 36% | -17% | 213% |
| 24 | 20% | -7% | -29% | -4% | -8% | 25% | 15% | 19% | -34% | -30% | -28% | -22% | -82% |
| 23 | -10% | -20% | -23% | -17% | -18% | 22% | 3% | 97% | 74% | -25% | -8% | 32% | 107% |
| 22 | -22% | 6% | -16% | -3% | -7% | -33% | -11% | 0% | -10% | 116% | -4% | -3% | 14% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.33B
P/E ratio
—
52W high
$28.41
52W low
$1.91
Volume
16,51,416
Beta
1.22
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tango Therapeutics, Inc. share price today?
- Tango Therapeutics, Inc. (TNGX) last traded around $20.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TNGX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TNGX. Download the app for real-time alerts.
- How can I analyze Tango Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.